Arterra Bioscience SpA (MIL:ARBS) ROCE %: 13.76% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:ARBS Arterra Bioscience SpA MIL:ARBS
77 GF Score
Price €3.04
GF Value €2.91
Valuation Fairly Valued
View Full Analysis

What is Arterra Bioscience SpA ROCE %?

Arterra Bioscience SpA MIL:ARBS -0.33% 77 ROCE % is 13.76% as of Dec. 2025. GuruFocus rates MIL:ARBS with a GF Score™ of 77/100 and a GF Value™ of €2.91 (Fairly Valued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Arterra Bioscience SpA's annualized ROCE % for the quarter that ended in Dec. 2025 was 13.76%.

Arterra Bioscience SpA  (MIL:ARBS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Arterra Bioscience SpA ROCE % Related Terms

Arterra Bioscience SpA ROCE % Historical Data

* Premium members only.

The historical data trend for Arterra Bioscience SpA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arterra Bioscience SpA ROCE % Chart

Arterra Bioscience SpA Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only 13.05 16.58 11.35 14.02 15.21

Arterra Bioscience SpA Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.28 10.83 17.65 17.08 13.76
MIL:ARBS
77GF Score
Arterra Bioscience SpA MIL:ARBS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arterra Bioscience SpA ROCE % Calculation

Arterra Bioscience SpA's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=1.999/( ( (13.402 - 0.824) + (14.588 - 0.882) )/ 2 )
=1.999/( (12.578+13.706)/ 2 )
=1.999/13.142
=15.21 %

Arterra Bioscience SpA's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=1.826/( ( (14.01 - 1.183) + (14.588 - 0.882) )/ 2 )
=1.826/( ( 12.827 + 13.706 )/ 2 )
=1.826/13.2665
=13.76 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 13.76% mean?
Arterra Bioscience SpA (MIL:ARBS) has a ROCE % of 13.76% as of Dec. 2025.
Is Arterra Bioscience SpA's ROCE % too high?
Arterra Bioscience SpA's current ROCE % is 13.76%. Overall, Arterra Bioscience SpA has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's ROCE % compare to VRTX and REGN?
Arterra Bioscience SpA's ROCE % of 13.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Arterra Bioscience SpA's current ROCE % is 13.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.91, compared to a current price of €3.04 — trading 4.5% above its estimated fair value. The current ROCE % is 13.76%. Arterra Bioscience SpA's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current ROCE % is 13.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?

Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued. The current stock price of €3.04 is trading 4.5% above its estimated GF Value™ of €2.91. GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.

Key valuation signals for MIL:ARBS:

  • ROCE %: 13.76%
  • GF Value™: €2.91 vs. price of €3.04 (4.5% above fair value)
  • GF Score™: 77/100

No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arterra Bioscience SpA Business Description

Address via Benedetto Brin, 69, Napoli, ITA, 80142
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
77GF Score

Get the complete analysis for MIL:ARBS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.04
Price
€2.91
GF Value